Pharmaceuticals News

Marvel Biosciences’ Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

Quoin's paper on QRX003 mechanism of action and a pediatric Netherton Syndrome case report accepted for publication in Dermatology and Therapy.

First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability.Pixclara is the only FDA-approved radiopharmaceutical imaging drug for...

LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...

Company announcement no. 38 - 2606 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Resolution Therapeutics to present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026

Marks the fourth investment completed under Angelini Ventures’ €150 million co-investment partnership with the European Investment Bank in less than 12 months Regina Hodits from Angelini Ventures to...

Dr Koh brings extensive infectious disease and clinical development expertise as RQ Bio prepares to advance RQB01 into the clinicSenior appointments across CMC, clinical operations and programme...

Rewind Therapeutics secures financing to advance its oral GPR17 remyelination program for MS, supported by peer-reviewed preclinical data in PLOS ONE.

RougeTx Launches with $58 million Series A financing to advance first-in-class treatment for hereditary hemorrhagic telangiectasia (HHT).